Drug industry uses citizen petitions to block generics

11/8/2012 | Philadelphia Inquirer, The

The brand-name pharmaceutical industry is using citizen petitions as a means to challenge generic competitors, something that generic-drug-makers say is simply a tactic to delay generics and retain market share. The petitions "do raise concerns that the FDA should know about," said Rutgers-Camden law professor Michael A. Carrier, a co-author of a paper on the topic. "But a lot of petitions are filed by large companies in an effort to delay generic entry into the market."

View Full Article in:

Philadelphia Inquirer, The